India’s Natco Pharma will acquire significant stakes in 135-year-old South African pharmaceutical giant Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram becoming a privately-held entity co-owned by...
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic...
Life sciences companies may turn to spin-offs to avoid sell-offs
Big Pharma continues its hunt for innovation, and with uncertain market and regulatory conditions, some life sciences companies may be feeling the pressure to make their M&A exit or need additional funding in this...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark’s Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said in a statement on Monday. The planned...
Lupin to acquire VISUfarma to broaden its portfolio of ophthalmic biz
Lupin announced its wholly owned subsidiary, Nanomi B.V. (Nanomi), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO...
Pfizer to buy obesity startup Metsera for $4.9 billion
Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for...
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera, the Financial Times reported on Sunday, citing unidentified sources. The U.S. pharma firm will acquire New York City-based...
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs. The deal would help Roche...
Novo Holdings in talks to buy into Surya Hospitals
Novo Holdings, a 142 billion euro investment firm that controls drug maker Novo Nordisk, has entered into exclusive talks to acquire a 49% stake in Mumbai-based Surya Hospitals, said people familiar with the matter. A...
GTCR to Acquire Zentiva in $4.8 Billion Deal
Private equity firm GTCR has agreed to acquire Czech generic drugmaker Zentiva from Advent International in a transaction valued at €4.1 billion ($4.8 billion), according to reports in the Financial Times. The deal...
Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand
Dr Reddy’s Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire the Stugeron brand across the EMEA regions, with India and Vietnam as key markets...
Private equity firm Advent to sell generic drugmaker Zentiva to GTCR
Czech generic drugmaker Zentiva said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value. The deal values the Prague-based company at slightly...
